Oneness Biotech Co

Oneness Biotech Co EBITDA per Employee

The EBITDA per Employee of Oneness Biotech Co (4743.TWO) as of Nov 2, 2026 is -66.59 M TWD. In the previous year, EBITDA per Employee was -90.45 M TWD — a change of -26.38% (higher).

EBITDA per Employee

-66.59 MTWD

YoY

-26.38%

Last updated:

EBITDA per Employee of Oneness Biotech Co is 2025 -66.59 M TWD. EBITDA per Employee of Oneness Biotech Co was 2024 -90.45 M TWD. It decreases by -26.38% higher compared to the previous year.

The Oneness Biotech Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-20.39 M TWD
Jan 1, 2019
-26.67 M TWD
Jan 1, 2020
-20.40 M TWD
Jan 1, 2021
-32.59 M TWD
Jan 1, 2022
38.02 M TWD
Jan 1, 2023
-91.39 M TWD
Jan 1, 2024
-90.45 M TWD
Jan 1, 2025
-66.59 M TWD
The Oneness Biotech Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-66.59 MTWD-26.38%
-90.45 MTWD-1.02%
-91.39 MTWD-340.37%
38.02 MTWD-216.66%
-32.59 MTWD+59.77%
-20.40 MTWD-23.51%
-26.67 MTWD+30.78%
-20.39 MTWD+57.18%
-12.97 MTWD+37.58%
-9.43 MTWD+16.40%
-8.10 MTWD-17.74%
-9.85 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Oneness Biotech Co Stock analysis

What does Oneness Biotech Co do? Oneness Biotech Co., Ltd. generates revenue through the research and development of new drugs and the sale of pharmaceutical products and health products. The company focuses on health supplies, health food, and healthy food as its main products, which are distributed domestically. It also develops new drugs for treating chronic diabetic foot ulcers and anticancer drugs, targeting the domestic market for both its existing and new product lines. The firm's primary customers are domestic consumers seeking health and pharmaceutical solutions, including those requiring wound healing treatments for diabetic foot ulcers and anticancer therapies. Its product portfolio includes health supplies, health food, healthy food, and specialized drug developments, all sold within Taiwan's domestic market. Oneness Biotech's business model centers on developing and selling health and pharmaceutical products, with a particular emphasis on niche medical applications like diabetic foot ulcer treatments and cancer drugs. The company leverages its domestic distribution network to reach consumers interested in health-focused solutions and specialized medical treatments. Oneness Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oneness Biotech Co stock

EBITDA per Employee of Oneness Biotech Co is -66.59 M TWD in 2025.

EBITDA per Employee of Oneness Biotech Co changed from -90.45 M TWD to -66.59 M TWD, representing a -26.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Oneness Biotech Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Oneness Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Oneness Biotech Co

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Oneness Biotech Co